Cargando…
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study
BACKGROUND: There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of patients with aHUS treated with eculizumab. METHODS: Patients with aHUS who pa...
Autores principales: | Menne, Jan, Delmas, Yahsou, Fakhouri, Fadi, Licht, Christoph, Lommelé, Åsa, Minetti, Enrico E., Provôt, François, Rondeau, Eric, Sheerin, Neil S., Wang, Jimmy, Weekers, Laurent E., Greenbaum, Larry A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456946/ https://www.ncbi.nlm.nih.gov/pubmed/30971227 http://dx.doi.org/10.1186/s12882-019-1314-1 |
Ejemplares similares
-
Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study
por: Menne, Jan, et al.
Publicado: (2018) -
Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data
por: Tomazos, Ioannis, et al.
Publicado: (2022) -
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
por: Licht, Christoph, et al.
Publicado: (2015) -
Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment
por: Walle, Johan Vande, et al.
Publicado: (2016) -
Eculizumab treatment of atypical haemolytic uraemic syndrome: results from the largest prospective clinical trial to date
por: weekers, LE, et al.
Publicado: (2014)